Executive Director and Head of External Science & Innovation
Cambridge Massachusetts UNITED STATES
Dr. Yuan-hua Ding Is An Executive Director And Head Of Pfizer External Science & Innovation (Es&i) – Asia/pacific, Pfizer Worldwide Research & Development (Wrd). He Is Also A Member Of The Es&i Leadership Team. In This Capacity, He Partners With Colleagues In Es&i, Pfizer Business Development Group And Pfizer Asia Country Offices To Evaluate Technologies And Assets From Asia Pacific Academic, Biotech & Pharma Laboratories, Seek Opportunities To Incubate Early Biotech Companies, Build And Manage A Research Network Of Academic Institutes, Biotech & Pharma Companies, And Venture Capital Groups As Well As Regional Bioparks. He Liaises With Therapeutic Area And Technology Research Unit Leaderships In Accessing The Sciences, Technologies And Products Needed To Support Pfizer R&d Mission. Prior To His Current Job, Dr. Ding Served A Variety Of Roles In The Pfizer R&d Division, Including Head Of Asia External Science And Technology, Head Of Structural Biology At The Research Technology Center (Rtc) In Cambridge, Ma, Associate Research Fellow And Senior Research Scientist. As The Head Of The Rtc Structural Biology, He Oversaw A Group Of Scientists Responsible For Protein Production, Characterization, Crystallization, Crystallography And Structure-based Drug Design. His Group Supported Structural Based Drug Design Portfolio Of 10+ Programs, Through Collaborative Efforts With Rtc, Pfizer Global Structural Biology Groups And Therapeutic Area Project Teams, Covering Oncology, Diabetes, Inflammation And Cns. He Also Served As Project Leaders For Several Drug Discovery Programs With Some Into The Clinics. Dr. Ding Received A Bachelor’s Degree In Electronic Engineering From Peking University In 1987 And A Master’s Degree In Biophysics From Tsinghua University In 1990. In 1996, After Completion Of Doctoral Studies In Biochemistry With Prof. John Rosenberg And Roger Hendrix At The University Of Pittsburgh, He Moved To Harvard University To Become A Postdoctoral Fellow With Prof. Don Wiley. Dr. Ding’s Postdoctoral Work Focused On Structural And Biophysical Aspects Of Molecular Interactions Among T-cell Receptor (Tcr), Major Histocompatibility Complex (Mhc) And Peptide Antigens. While In Dr. Wiley’s Lab, Dr Ding Also Collaborated With Dr. Judah Folkman Of Boston Children’s Hospital On Structural Studies Of Endostatin, A Protein Shown To Be A Potent Angiogenesis Inhibitor In Mouse Model.

Emerging Opportunities in Global Markets

11:45 AM–5:00 PM Jun 4, 2018 (US - Eastern)

Room 253ABC, Level 2

Katherine AndersenHead of Healthcare Corporate Finance and East/Central Life Science atSilicon Valley Bank Mr. Michael ChanSenior Vice President atHong Kong Exchanges and Clearing Limited (HKEX) Helen ChenManaging Director, Head of L.E.K. China and Asia Life Sciences atL.E.K. Consulting Tony ChenPartner atJones Day Shanghei Joseph DamondExecutive Vice President, International Affairs atBiotechnology Innovation Organization Yuan-Hua DingExecutive Director and Head of External Science & Innovation atPfizer Inc. Monica H.Director, International Affairs atBiotechnology Innovation Organization Edward HuChief Financial Officer and Chief Investment Officers atWuXi AppTec Kewen JinManaging Partner atSerica Partners Alex JungPartner/Managing DIrector atEY-Parthenon Wei LiFounding Partner at6 Dimensions Capital Micah MackisonSenior VP for Corporate Development and Strategy atAssembly Biosciences Wendy PanBoard of Directors atBayHelix Donghui QinDirector of Innovation atFerring Pharmaceuticals Greg ScottFounder and Chairman atChinaBIO Group Victor ShiChairman atBayHelix Alan TurleyDeputy Assistant Secretary for China atU.S. Department of Commerce Jonathan WangSenior VP and Head of Business Development atZai Lab Lijun WuChief Scientific Officer and Senior VP R&D, Fosun Pharma USA atShanghai Henlius Biotech Haishan XiongSenior Vice President for Business Development atFountain Medical Development GE YanfengDirector-General of the Research Department of Social Development atDevelopment Research Center of the State Council (DRC) Debra YuManaging Director atChina Renaissance Securities (US) Inc.
None yet.